12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Myfortic mycophenolic acid regulatory update

FDA approved a single REMS for all immunosuppressants containing mycophenolate to address the risks of first-trimester miscarriage and congenital birth defects. The REMS includes an education program for prescribers, a medication guide, a registry for pregnant women and educational tools to help prescribers...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >